The Australian Therapeutic Goods Administration (TGA) has conducted a review of transvaginal mesh patch devices and found little evidence to support the overall effectiveness of the surgical mesh. The TGA will now reassess clinical trials conducted on individual transvaginal mesh products to determine their safety.
Trasnvaginal mesh patches were approved to treat conditions such as pelvic organ prolapse (POP) and stress urinary incontinence (SUI), but were soon found to fail and cause patients severe complications. Tens of thousands of transvaginal mesh side effects complaints have been filed by American women who have suffered injuries from the devices.
Several companies have issued transvaginal mesh recalls for their products after studies showed transvaginal mesh can lead to internal bleeding, tissue damage and severe pain. Thousands of transvaginal mesh lawsuits have been filed against mesh manufacturers alleging that the devices caused serious injuries.